Citicoline and Piracetam in Cerebellar Ataxia - A Neurologist's Perspective

1. Piracetam

• Design: 8 patients with autosomal dominant cerebellar ataxia (ADCA), uncontrolled clinical trial
• Intervention: IV piracetam 60 g/day for 14 days (extremely high dose)
• Outcome: Statistically significant improvement in International Cooperative Ataxia Rating Scale (ICARS) total score (p=0.018); subscale analysis significant only for posture and gait disturbances (p=0.018)
• Conclusion: The authors considered this "good clinical observation in favour of high dose piracetam infusion to reduce disability by improving gait ataxia"

• Only 8 patients - severely underpowered
• No placebo control - open-label, no blinding
• IV route at 60 g/day - this is NOT an oral maintenance dose; oral bioequivalence would require even higher impractical doses
• Short observation period (14 days) - no data on sustained benefit
• No replication in a larger RCT since 2008
• Not endorsed by any neurological guideline (AAN, EAN, MDS)

2. Citicoline (CDP-choline)

• Hall et al. (2020, PLoS One; PMID 32053612) - Open-label pilot in Fragile X-associated tremor/ataxia syndrome (FXTAS)
• Dose: 1000 mg/day orally for 12 months
• Results: No significant improvement in ataxia scores (FXTAS Rating Scale); stability was maintained (not deterioration); only cognitive measures (Beck Anxiety Inventory, Stroop Color-Word) improved significantly
• Conclusion: Safe and well-tolerated in FXTAS; no proven anti-ataxia benefit

3. Context: What Actually Works in Cerebellar Ataxia?

4. Practical Bottom Line (From a Clinical Standpoint)

• May offer modest symptomatic benefit for gait ataxia when used at high doses (IV 60 g/day short course, or oral 16-24 g/day) in degenerative or hereditary cerebellar ataxia
• Evidence is weak (single small uncontrolled trial)
• Reasonable empirical trial in patients with prominent gait ataxia or co-existing cortical myoclonus (PME), where risk-benefit is favorable given its safety profile
• Not recommended routinely as a disease-modifying agent

• No meaningful evidence for cerebellar ataxia of any etiology
• Use in ataxia patients is extrapolated from stroke/vascular indications - this extrapolation is not supported
• May be considered in patients who have concurrent vascular risk factors or acute ischemic insults contributing to their cerebellar syndrome
• Should not be prescribed primarily as an anti-ataxia drug

1. Establish the exact etiology of ataxia (SCA genotyping, immune workup, vitamin levels, MRI)
2. For autoimmune ataxias - immunotherapy (steroids, IVIG, rituximab)
3. For EA2/SCA6 - acetazolamide or 4-AP
4. For all degenerative ataxias - intensive physiotherapy is the only intervention with strong RCT evidence (2025 Frontiers meta-analysis)
5. For riluzole - reasonable off-label option for SCAs (SCA2/3/6 data exists)
6. Piracetam - empirical trial acceptable if other options exhausted; document response objectively using SARA/ICARS
7. Citicoline - no justification for primary ataxia indication

Mrs. Indu Batish - Case Analysis

Clinical Summary

• Dysdiadochokinesia bilateral
• Finger-nose test positive
• Tandem walk impaired
• No nystagmus
• DTRs ALL brisk (+++)

• Cerebellar atrophy with prominent CSF spaces in bilateral cerebellar hemispheres and brainstem - radiologist's impression: "Rule out MSA-C"
• No focal parenchymal signal abnormality
• No diffusion restriction
• Cerebral hemispheres normal

• C4-5 asymmetric diffuse disc bulge - bilateral neural foraminal narrowing, bilateral exiting nerve root indentation (R>L)
• No cord signal change

Prescription Evolution - Three Visits

• Escitalopram increased to 1 tab morning + ½ tab night (worsening depression/anxiety)
• Switched from Quogress to Magrium (added magnesium, Vit B2)
• Added Levocarnitine + Vit E
• Advised electric wheelchair - functional decline
• Notes: over-dependence on walker, poor fluid intake, not taking capsule, stress incontinence

Clinical Interpretation

1. Cerebellar ataxia (gait > limb) with brisk DTRs - this combination (cerebellar + pyramidal) is a red flag for MSA-C
2. MRI: cerebellar + brainstem atrophy (classic "hot cross bun" sign on axial pons is not mentioned but likely needs review)
3. Stress incontinence - autonomic dysfunction (a defining feature of MSA)
4. SCA panel negative
5. Progressive course despite treatment
6. No nystagmus (distinguishes from episodic ataxia)

• Orthostatic hypotension documentation (BP lying vs standing) - autonomic
• Formal autonomic testing
• PET/DATscan (not always necessary)
• The MRI report does not mention "hot cross bun sign" - would be worth reviewing the axial pons sequences
• Functional MRI/MSA biomarkers if available

Now - Back to Your Original Question

What Should Be Considered Going Forward

1. MSA-C has no disease-modifying treatment as of 2026. Focus is on quality of life, symptom management, and safety.
2. Autonomic management - if postural hypotension is present (very likely given MSA-C): fludrocortisone, midodrine, droxidopa; ensure adequate salt/fluid intake (she's noted to "take less water" - this is dangerous in dysautonomia)
3. Urinary incontinence (stress type noted) - urological/urogynae evaluation; oxybutynin or mirabegron for detrusor overactivity; pelvic floor physio
4. Speech and swallowing assessment - MSA-C patients develop dysarthria and dysphagia; aspiration risk in a bronchial asthma patient is particularly dangerous
5. Physiotherapy - intensive coordinative physiotherapy has the strongest evidence base (2025 meta-analysis, Frontiers Neurology) for maintaining function in cerebellar ataxia
6. No role for citicoline or piracetam in this specific patient - MSA-C is an alpha-synucleinopathy and there is no mechanistic or clinical trial rationale for either drug here
7. Riluzole - there is phase II RCT evidence for cerebellar ataxia; while most data is in SCAs, some benefit seen in MSA-C patients too - worth discussing with the treating neurologist as an option

Piracetam + Citicoline + Astaxanthin in Mrs. Indu Batish (?MSA-C)

1. Piracetam

• One small uncontrolled trial - 8 ADCA patients, IV 60g/day for 14 days - significant gait improvement (ICARS, p=0.018)
• Zero evidence specifically in MSA-C
• MSA-C is an alpha-synucleinopathy (glial cytoplasmic inclusions, SNCA pathology) - fundamentally different pathophysiology from ADCA

• The study that showed benefit used IV 60g/day - a dose that is impractical for outpatient maintenance
• Typical oral doses prescribed in India (800mg TID to 2.4g/day) are pharmacologically different from the evidence dose
• Anti-myoclonic doses (16-24g/day orally) may have modest GABAergic cerebellar effect but she has no documented myoclonus
• If the dose being given is standard 800mg-2.4g/day oral, the honest answer is: unlikely to do much for ataxia specifically

2. Citicoline

• Only trial with cerebellar ataxia = FXTAS pilot (n=10, citicoline 1000mg/day, 12 months) - ataxia scores did not improve, only stability was maintained, with cognitive benefit
• No trial in MSA-C at all
• PubMed search today returned zero results for citicoline + MSA or citicoline + cerebellar ataxia (outside FXTAS)

• Neuroprotection via membrane phospholipid synthesis (phosphatidylcholine)
• Reduces glutamate excitotoxicity
• Enhances dopaminergic and cholinergic transmission
• Well-proven in acute ischemic stroke and vascular cognitive impairment - that's where the evidence is solid

3. Astaxanthin - the Interesting One

• Neutralises reactive oxygen species (ROS) and reactive nitrogen species (RNS)
• Reduces mitochondrial dysfunction and preserves ATP production
• Inhibits neuroinflammation (NF-κB, TNF-α suppression)
• Anti-apoptotic (Bcl-2 upregulation, cytochrome-c suppression)
• Reduces alpha-synuclein aggregation in animal models - directly relevant to MSA-C pathology

• PubMed returned zero results for astaxanthin + cerebellar ataxia or MSA
• Animal studies: promising in Parkinson's models, oxidative stress models, spinocerebellar ataxia models (mouse)
• One animal study (2025, Mol Neurobiol - PMID 41276706): astaxanthin-loaded nanoparticles reduced 6-OHDA-induced Parkinson's pathology via PI3K/Akt/mTOR pathway in rats
• Human clinical trials: primarily in age-related cognitive decline, fatigue, metabolic syndrome - no neurological disease trials of significance published to date
• No human trial in MSA, SCA, or any progressive cerebellar ataxia

The Overall Picture of the Combination

Most Important Point